Odefsey and Complera

rilpivirine, emtricitabine, tenofovir AF RPV (NNRTI), FTC and TAF (two NRTIs) and rilpivirine, emtricitabine, tenofovir DF RPV (NNRTI), FTC and TDF (two NRTIs)

Other complete HIV regimens, DHHS recommended initial therapy in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily, with a standard meal. For people taking HIV therapy for the first time (treatment-naïve) or people with suppressed viral load on a stable HIV regimen for at least six months who have no known resistance to the components of the regimen: rilpivirine, emtricitabine, or tenofovir.

For adults and children 12 years of age and older weighing at least 77 pounds (35 kg) and having a CrCl of at least 30 mL/min for Odefsey or 50 mL/min for Complera. Odefsey should be used with caution in adults with end-stage renal disease (ESRD) with an estimated CrCl below 15 mL/min who are receiving chronic hemodialysis (HD). Take the Odefsey dose after completion of dialysis. Complera should not be used in people with CrCl less than 50 mL/min or severe liver impairment.

Must be taken with food that you chew—not just nutritional drinks, protein shakes, or a light snack. Taking rilpivirine without enough food could result in up to a 40% decrease in drug absorption and may lead to resistance.

According to DHHS guidelines, people taking HIV treatment for the first time should have an HIV RNA (viral load) of less than 100,000 copies/mL and CD4 T cell count must be above 200 cells/mm3 before starting rilpivirine due to higher rates of virologic failure in these people. The CD4 requirement, however, is no longer on the drug label.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.
  • See the individual drugs: Edurant, Descovy (coformulation of Emtriva and TAF), or Truvada (coformulation of Emtriva and TDF).
  • See package insert for more complete information on potential side effects and interactions.


Gilead Sciences, Inc.
gilead.com; genvoya.com
(800) GILEAD-5 (445-3235)

Janssen Therapeutics
(800) JANSSEN (526-7736)


Odefsey AWP

Complera AWP

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments